"I would consider when sleeping to keep one eye open on Multiple Sclerosis"
I totally agree. We're even now have statistically significant mean reduction in Thrombospondin-1 (-49%), and increases in LTBP4 (20.7%), soluble
CXCL16 (29.9%), and VCAM-1 (18.0%) compared to baseline levels (FDR p-value <0.0005) to support ATL1102 in DMD ..
As Mark Diamond once said, "If we show good activity in DMD that could be highly supportive of an MS study." I believe the company will pursue further in this area when the time comes.
Anp at world muscle society, page-36
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.3¢ |
Change
-0.002(2.35%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 8.9¢ | 8.3¢ | $17.65K | 207.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30001 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 60208 | 2 |
View Market Depth
| Last trade - 12.34pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
8.3¢ |
Change
-0.002 ( 4.60 %) |
||||
| Open | High | Low | Volume | ||
| 8.9¢ | 8.9¢ | 8.3¢ | 70074 | ||
| Last updated 12.40pm 07/06/2024 ? | |||||
| PER (ASX) Chart |